- Home
- EEA vs SER Comparison
EEA vs SER Comparison
Compare EEA & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EEA
- SER
- Stock Information
- Founded
- EEA 1986
- SER 2017
- Country
- EEA Germany
- SER United States
- Employees
- EEA N/A
- SER N/A
- Industry
- EEA Trusts Except Educational Religious and Charitable
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- EEA Finance
- SER Health Care
- Exchange
- EEA Nasdaq
- SER Nasdaq
- Market Cap
- EEA 66.7M
- SER 56.5M
- IPO Year
- EEA N/A
- SER 2018
- Fundamental
- Price
- EEA $10.19
- SER $5.80
- Analyst Decision
- EEA
- SER Strong Buy
- Analyst Count
- EEA 0
- SER 1
- Target Price
- EEA N/A
- SER $11.00
- AVG Volume (30 Days)
- EEA 9.2K
- SER 14.1K
- Earning Date
- EEA 01-01-0001
- SER 08-08-2025
- Dividend Yield
- EEA 1.92%
- SER N/A
- EPS Growth
- EEA N/A
- SER N/A
- EPS
- EEA N/A
- SER N/A
- Revenue
- EEA N/A
- SER $51,000.00
- Revenue This Year
- EEA N/A
- SER N/A
- Revenue Next Year
- EEA N/A
- SER N/A
- P/E Ratio
- EEA N/A
- SER N/A
- Revenue Growth
- EEA N/A
- SER N/A
- 52 Week Low
- EEA $7.45
- SER $3.81
- 52 Week High
- EEA $9.26
- SER $11.57
- Technical
- Relative Strength Index (RSI)
- EEA 71.33
- SER 57.53
- Support Level
- EEA $9.85
- SER $5.50
- Resistance Level
- EEA $10.18
- SER $6.29
- Average True Range (ATR)
- EEA 0.11
- SER 0.52
- MACD
- EEA 0.01
- SER 0.03
- Stochastic Oscillator
- EEA 97.58
- SER 74.44
About EEA The European Equity Fund Inc.
European Equity Fund, Inc / MD is a United States-based diversified, closed-end management investment company. The fund seeks long-term capital appreciation through investment in equity and equity securities of issuers domiciled in Europe. Its portfolio of investments consists of different sectors such as industrials, financials, healthcare, consumer discretionary, materials, consumer staples, information technology, and other sectors.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.